Assembly

Assembly Biosciences is a clinical-stage biotechnology company dedicated to developing next-generation small molecule therapeutics for serious viral diseases. The company's primary focus is on achieving a functional cure for chronic hepatitis B virus (HBV) infection through its portfolio of potent core protein allosteric modulators (CpAMs). Beyond HBV, Assembly is advancing candidates for recurrent genital herpes and other high-burden viral infections, such as hepatitis D and transplant-associated viruses. In 2023, the company entered into a significant 12-year strategic collaboration with Gilead Sciences to accelerate the development of its virology pipeline. Assembly's approach leverages deep expertise in viral biology to target validated mechanisms with differentiated, orally bioavailable molecules.